Login / Signup

Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone‒Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Jordi StiraCarmen GravinaRiccardo LombardoCosimo De Nunzio
Published in: The Journal of urology (2023)
Keyphrases
  • prostate cancer
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes
  • patient reported